awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q36824869-1AC9DCED-B5F5-4631-9173-F0696A3D3CB0
Q36824869-1AC9DCED-B5F5-4631-9173-F0696A3D3CB0
BestRank
Statement
http://www.wikidata.org/entity/statement/Q36824869-1AC9DCED-B5F5-4631-9173-F0696A3D3CB0
Efficacy, safety and administration timing of trastuzumab in human epidermal growth factor receptor 2 positive breast cancer patients: A meta-analysis
P2860
Q36824869-1AC9DCED-B5F5-4631-9173-F0696A3D3CB0
BestRank
Statement
http://www.wikidata.org/entity/statement/Q36824869-1AC9DCED-B5F5-4631-9173-F0696A3D3CB0
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
3a2cbc49026806da58518c2b04a1404bc65f8efc
P2860
A multicenter randomized phase II study of sequential epirubicin/cyclophosphamide followed by docetaxel with or without celecoxib or trastuzumab according to HER2 status, as primary chemotherapy for localized invasive breast cancer patients.